Is CAR T cell therapy possible at this moment for me

CAR-T Cell Therapy for Pancreatic Cancer: What You Should Know

Based on your pancreatic adenocarcinoma diagnosis, I want to give you a straightforward answer about CAR-T cell therapy and where it stands for your situation.

The Current Reality for Pancreatic Cancer

CAR-T cell therapy is NOT currently an established treatment option for pancreatic adenocarcinoma. Here's why:

CAR-T cells are engineered immune cells designed to recognize and attack cancer cells with specific protein targets. They've been FDA-approved and show strong results for certain blood cancers (like lymphomas and leukemias), but pancreatic cancer presents unique challenges:

• Limited targetable antigens: Pancreatic tumors don't have the same clear protein "targets" that blood cancers do
• Solid tumor barriers: CAR-T cells struggle to penetrate and work effectively in solid tumors like pancreatic cancer
• Immunosuppressive environment: Pancreatic tumors create an environment that suppresses immune cell activity

According to NCCN Guidelines for Pancreatic Adenocarcinoma, CAR-T therapy is not listed as a standard treatment option for metastatic pancreatic cancer at this time.

What IS Being Explored

There are clinical trials investigating CAR-T approaches for pancreatic cancer, but these are still in research phases. Given your treatment history (FOLFIRINOX, RMC-6236, and now gemcitabine/abraxane + avutometinib/defactinib), you may be a candidate for emerging immunotherapy trials.

Questions to Ask Your Oncologist

1. "Are there any CAR-T or other cellular immunotherapy clinical trials I might be eligible for?"
2. "Given my current treatment response, what emerging therapies should we be monitoring?"
3. "Are there trials combining CAR-T with chemotherapy for pancreatic cancer?"
4. "What clinical trial databases should I check regularly?" (ClinicalTrials.gov, your cancer center's trial portal)

Your Current Treatment Strategy

Your current regimen (gemcitabine/abraxane + avutometinib/defactinib) is a more proven approach for your situation. The addition of targeted therapy based on your biomarker profile is aligned with ASCO and NCCN recommendations for metastatic pancreatic cancer.

Note on your biomarkers: Your pMMR (proficient mismatch repair) status and the absence of KRAS/BRCA mutations you mentioned in your recent questions are important for understanding what targeted therapies may help—this is exactly what your current treatment addresses.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.